PE20020103A1 - Derivados de 1-sulfonil-pirrolidina - Google Patents
Derivados de 1-sulfonil-pirrolidinaInfo
- Publication number
- PE20020103A1 PE20020103A1 PE2001000638A PE2001000638A PE20020103A1 PE 20020103 A1 PE20020103 A1 PE 20020103A1 PE 2001000638 A PE2001000638 A PE 2001000638A PE 2001000638 A PE2001000638 A PE 2001000638A PE 20020103 A1 PE20020103 A1 PE 20020103A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfonyl
- phenyl
- alkyl
- pyrrolidine
- fluor
- Prior art date
Links
- -1 4-FLUOR-PHENYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 abstract 1
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Surgery (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE 1-SULFONIL-PIRROLIDINA DE FORMULA I DONDE R1 ES H, ARILO CON HALO; R2 ES ARILO CON HALOGENO, ALQUILO; R3 ES OR', CIANO, HALOGENO, N-HIDROXI-AMIDINO, C(O)-OR, HETEROARILO DE 1-4 HETEROATOMOS; R4 ES CICLOALQUILO, FENILO, ALQUILO; R ES ALQUILO; R' ES H, ALQUILO, CICLOALQUILO-ALQUILO. SON COMPUESTOS PREFERIDOS (2RS, 5RS)-5-{2-[5-(4-FLUOR-FENIL)-1-(TOLUENO-4-SULFONIL)-PIRROLIDIN-2-IL]-ETIL-3-METIL-[1,2,4]OXADIAZOL, (2RS, 5RS)-5-[5-(4-FLUOR-FENIL)-1-(TOLUENO-4-SULFONIL)-PIRROLIDIN-2-IL]-ETIL-2-METIL-2H-TETRAZOL, (2RS, 5RS)-5-{3-[5-(4-FLUOR-FENIL)-1-(TOLUENO-4-SULFONIL)-PIRROLIDIN-2-IL]-PROPIL}-2-METIL-2H-TETRAZOL, ENTRE OTROS. LOS DERIVADOS DE 1-SULFONIL-PIRROLIDINA PRESENTAN AFINIDAD POR LOS RECEPTORES METABOTROPICOS DEL GLUTAMATO Y SON UTILES PARA EL TRATAMIENTO DE TRASTORNOS NEUROLOGICOS COMO PSICOSIS, ESQUIZOFRENIA, ALZHEIMER
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00113894 | 2000-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020103A1 true PE20020103A1 (es) | 2002-02-13 |
Family
ID=8169121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000638A PE20020103A1 (es) | 2000-06-30 | 2001-06-27 | Derivados de 1-sulfonil-pirrolidina |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6589978B2 (es) |
| EP (1) | EP1299383B1 (es) |
| JP (1) | JP3994051B2 (es) |
| KR (1) | KR100529423B1 (es) |
| CN (1) | CN1178936C (es) |
| AR (1) | AR029288A1 (es) |
| AT (1) | ATE286895T1 (es) |
| AU (2) | AU8187701A (es) |
| BR (1) | BR0112093A (es) |
| CA (1) | CA2413243A1 (es) |
| CZ (1) | CZ2003280A3 (es) |
| DE (1) | DE60108394T2 (es) |
| DK (1) | DK1299383T3 (es) |
| EC (1) | ECSP024403A (es) |
| ES (1) | ES2234869T3 (es) |
| HR (1) | HRP20021023B1 (es) |
| HU (1) | HUP0301167A3 (es) |
| IL (2) | IL153425A0 (es) |
| JO (1) | JO2384B1 (es) |
| MA (1) | MA26923A1 (es) |
| MX (1) | MXPA02012270A (es) |
| MY (1) | MY126903A (es) |
| NO (1) | NO324218B1 (es) |
| NZ (1) | NZ523025A (es) |
| PE (1) | PE20020103A1 (es) |
| PL (1) | PL360396A1 (es) |
| PT (1) | PT1299383E (es) |
| RU (1) | RU2272026C2 (es) |
| SI (1) | SI1299383T1 (es) |
| TW (1) | TWI265928B (es) |
| UY (1) | UY26812A1 (es) |
| WO (1) | WO2002002554A1 (es) |
| YU (1) | YU99702A (es) |
| ZA (1) | ZA200209966B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040171614A1 (en) * | 2002-02-06 | 2004-09-02 | Schering-Plough Corporation | Novel gamma secretase inhibitors |
| US7256186B2 (en) | 2002-02-06 | 2007-08-14 | Schering Corporation | Gamma secretase inhibitors |
| TW200302717A (en) * | 2002-02-06 | 2003-08-16 | Schering Corp | Novel gamma secretase inhibitors |
| DE10240818A1 (de) | 2002-08-30 | 2004-05-13 | Grünenthal GmbH | Substituierte 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazol-Derivate |
| GB0225938D0 (en) * | 2002-11-06 | 2002-12-11 | Glaxo Group Ltd | Novel compounds |
| EP1740570A2 (en) * | 2004-04-05 | 2007-01-10 | Schering Corporation | Novel gamma secretase inhibitors |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| US7763613B2 (en) | 2004-06-30 | 2010-07-27 | Schering Corporation | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors |
| AR049726A1 (es) * | 2004-07-22 | 2006-08-30 | Schering Corp | Amidas sustituidas inhibidoras de beta secretasa |
| JP5173192B2 (ja) | 2004-09-30 | 2013-03-27 | 武田薬品工業株式会社 | プロトンポンプ阻害薬 |
| US20090042861A1 (en) * | 2005-04-04 | 2009-02-12 | Takeda Pharmaceutical Company Limited | Prophylactic or Therapeutic Agent for Depression or Anxiety Disorder |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258357A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
| NZ566378A (en) | 2005-08-30 | 2011-03-31 | Takeda Pharmaceutical | 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| EP1942879A1 (en) | 2005-10-31 | 2008-07-16 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| CN101553481A (zh) * | 2006-09-29 | 2009-10-07 | 格吕伦塔尔有限公司 | 取代的磺酰胺衍生物 |
| US8933105B2 (en) | 2007-02-28 | 2015-01-13 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| US8691816B2 (en) * | 2008-08-15 | 2014-04-08 | N30 Pharmaceuticals, Inc. | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents |
| US8969387B2 (en) | 2008-08-27 | 2015-03-03 | Takeda Pharmaceutical Company Limited | Pyrrole compounds |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2351323B1 (es) * | 2009-06-26 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para el descubrimiento de farmacos. |
| ES2351452B1 (es) * | 2009-07-01 | 2011-10-05 | Institut Univ. De Ciència I Tecnologia, S.A. | Bibliotecas de n-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica. |
| JPWO2022270628A1 (es) * | 2021-06-25 | 2022-12-29 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905979A (en) * | 1974-05-09 | 1975-09-16 | Stanford Research Inst | Diazabicyclooctanes and diazabicycloheptanes |
| US4539411A (en) * | 1982-02-05 | 1985-09-03 | Hoffmann-La Roche Inc. | Rhodium complexes of chiral phosphines |
| US5036153A (en) * | 1989-05-11 | 1991-07-30 | Braish Tamim F | Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates |
| US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| GB9612884D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| US6645939B1 (en) * | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
| WO1999026615A1 (en) | 1997-11-24 | 1999-06-03 | Merck & Co., Inc. | Cyclic amino acid derivatives as cell adhesion inhibitors |
| GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
| AT411339B (de) | 1998-05-13 | 2003-12-29 | Fronius Schweissmasch Prod | Verfahren zum steuern eines schweissgerätes und steuervorrichtung hierfür |
| PL345110A1 (en) | 1998-06-03 | 2001-12-03 | Gpi Nil Holdings | Aza-heterocyclic compounds used to treat neurological disorders and hair loss |
| KR20010081115A (ko) | 1998-12-18 | 2001-08-27 | 둘락 노먼 씨. | 파르네실 단백질 트랜스퍼라제 억제제 |
| EP1147097A1 (en) * | 1999-01-27 | 2001-10-24 | Ortho-Mcneil Pharmaceutical, Inc. | Peptidyl heterocyclic ketones useful as tryptase inhibitors |
| TW575561B (en) | 1999-03-25 | 2004-02-11 | Hoffmann La Roche | 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives |
| ES2296618T3 (es) * | 1999-05-20 | 2008-05-01 | Dong Wha Pharmaceutical Industrial Co. Ltd. | Derivados opticamente activos de acidos quinolin-carboxilicos que tienen sustituyentes de 7-pirrolidina que provocan actividad optica y un procedimiento para la preparacion de estos. |
| US6143776A (en) * | 2000-02-02 | 2000-11-07 | Sunesis Pharmaceuticals, Inc. | Tosylproline analogs as thymidylate synthase inhibitors |
-
2001
- 2001-06-13 US US09/880,539 patent/US6589978B2/en not_active Expired - Fee Related
- 2001-06-14 TW TWSULFONYL-A patent/TWI265928B/zh not_active IP Right Cessation
- 2001-06-22 ES ES01960365T patent/ES2234869T3/es not_active Expired - Lifetime
- 2001-06-22 WO PCT/EP2001/007135 patent/WO2002002554A1/en not_active Ceased
- 2001-06-22 IL IL15342501A patent/IL153425A0/xx active IP Right Grant
- 2001-06-22 AU AU8187701A patent/AU8187701A/xx active Pending
- 2001-06-22 AU AU2001281877A patent/AU2001281877B2/en not_active Ceased
- 2001-06-22 EP EP01960365A patent/EP1299383B1/en not_active Expired - Lifetime
- 2001-06-22 PT PT01960365T patent/PT1299383E/pt unknown
- 2001-06-22 JP JP2002507806A patent/JP3994051B2/ja not_active Expired - Fee Related
- 2001-06-22 NZ NZ523025A patent/NZ523025A/en unknown
- 2001-06-22 KR KR10-2002-7017967A patent/KR100529423B1/ko not_active Expired - Fee Related
- 2001-06-22 YU YU99702A patent/YU99702A/sh unknown
- 2001-06-22 DK DK01960365T patent/DK1299383T3/da active
- 2001-06-22 AT AT01960365T patent/ATE286895T1/de not_active IP Right Cessation
- 2001-06-22 DE DE60108394T patent/DE60108394T2/de not_active Expired - Fee Related
- 2001-06-22 HR HR20021023A patent/HRP20021023B1/xx not_active IP Right Cessation
- 2001-06-22 BR BR0112093-0A patent/BR0112093A/pt not_active IP Right Cessation
- 2001-06-22 CA CA002413243A patent/CA2413243A1/en not_active Abandoned
- 2001-06-22 HU HU0301167A patent/HUP0301167A3/hu unknown
- 2001-06-22 CZ CZ2003280A patent/CZ2003280A3/cs unknown
- 2001-06-22 RU RU2003100516/04A patent/RU2272026C2/ru not_active IP Right Cessation
- 2001-06-22 PL PL36039601A patent/PL360396A1/xx unknown
- 2001-06-22 MX MXPA02012270A patent/MXPA02012270A/es active IP Right Grant
- 2001-06-22 CN CNB01812061XA patent/CN1178936C/zh not_active Expired - Fee Related
- 2001-06-22 SI SI200130290T patent/SI1299383T1/xx unknown
- 2001-06-26 JO JO2001100A patent/JO2384B1/en active
- 2001-06-27 PE PE2001000638A patent/PE20020103A1/es not_active Application Discontinuation
- 2001-06-27 MY MYPI20013048 patent/MY126903A/en unknown
- 2001-06-27 AR ARP010103053A patent/AR029288A1/es not_active Application Discontinuation
- 2001-06-29 UY UY26812A patent/UY26812A1/es not_active Application Discontinuation
-
2002
- 2002-12-09 ZA ZA200209966A patent/ZA200209966B/en unknown
- 2002-12-12 IL IL153425A patent/IL153425A/en not_active IP Right Cessation
- 2002-12-26 EC EC2002004403A patent/ECSP024403A/es unknown
- 2002-12-27 MA MA26983A patent/MA26923A1/fr unknown
- 2002-12-27 NO NO20026263A patent/NO324218B1/no unknown
-
2003
- 2003-03-26 US US10/397,908 patent/US6995182B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020103A1 (es) | Derivados de 1-sulfonil-pirrolidina | |
| PE59999A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona-8-sustituidos | |
| PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
| FI943247A0 (fi) | Piperatsiinijohdannaisia 5-HT-reseptoriantagonisteina | |
| PE20020298A1 (es) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona como antagonistas de receptores de neuroquinina nk-1 | |
| PE20021041A1 (es) | DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2 | |
| PE20090297A1 (es) | Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogenesis | |
| PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
| FI942635A0 (fi) | Piperatsiinijohdannaiset 5HT1A-antagonisteina | |
| PE20030200A1 (es) | Bencimidazol como inhibidores de las map quinasas | |
| PE68799A1 (es) | Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina | |
| EA200601076A1 (ru) | Применение производных n-арилгидразина для борьбы с вредителями | |
| PE133799A1 (es) | Antagonistas del receptor de trombina | |
| DE69418789D1 (de) | 2-(Piperidin-4-yl, Pyridin-4-yl und Tetrahydropyridin-4-yl)-benzofuran-7-carbamat Derivate, ihre Herstellung und Verwendung als Acetylcholinesterase Inhibitoren | |
| ATE330930T1 (de) | Neue ethylaminderivate | |
| PE20050587A1 (es) | Derivados de diazindol-dicarbonilo-piperazinilo como agentes antivirales | |
| AR045791A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina | |
| FI914910A0 (fi) | Heterocykliska foereningar. | |
| KR880003920A (ko) | 피리다지논 유도체 | |
| PE20091348A1 (es) | Derivados de 1,2,4-triazol amino como moduladores de mglur5 | |
| PE20011266A1 (es) | Derivados de 1,4-diazepan-2,5-diona | |
| NO20065863L (no) | 3-[4-(6-(4,5-dihydroisoksazol-3-yl]pyridin-3-yl)-3-fenyl]-5-(1 H,1,2,3-triazol-1-yl-metyl)-1,3-oksazolidin-2-oner som antibakterielle midler | |
| JP2000204079A5 (es) | ||
| HUT50777A (en) | Process for producing 2-/3-pyridyl/-3-phenoxy-propionitril derivatives and intermediates and fungicide compositions containing the former ones as active components | |
| FI956151A0 (fi) | Iskeemisissä taudeissa käyttökelpoisia bentseenijohdannaisia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |